Skip to main content

Qiagen's $1.6B Bid for Digene Passes Federal Waiting Period

NEW YORK (GenomeWeb News) — Qiagen today said that federal regulators have cleared its planned acquisition of Digene.
 
The company said the Hart-Scott-Rodino antitrust deadline passed on midnight yesterday without a hitch, enabling the shop to buy Digene for $1.6 billion.
 
The deal is subject to the tender of a majority of Digene's common stock on a fully diluted basis before 11:59 p.m. EST on July 20, unless the offer is extended, as well as approval by Qiagen’s shareholders, among other conditions.
 
Qiagen said it expects to close the acquisition in August or September.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.